Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Toxicity/Feasibility Study: Combined Modality Treatment With Transimmunization for Non-Small Cell Lung Cancer

NCT00265603 is registered in ClinicalTrials.gov with Atlantic Health System as lead sponsor.

NCT NCT00265603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00265603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Toxicity/Feasibility Study: Combined Modality Treatment With Transimmunization for Non-Small Cell Lung Cancer
Lead sponsor
Atlantic Health System
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2004
Completion date
April 30, 2009
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer